Your browser is no longer supported. Please, upgrade your browser.
Magenta Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.95 Insider Own11.79% Shs Outstand48.26M Perf Week-4.09%
Market Cap404.59M Forward P/E- EPS next Y-1.75 Insider Trans0.00% Shs Float42.61M Perf Month4.19%
Income-80.00M PEG- EPS next Q-0.42 Inst Own70.70% Short Float4.40% Perf Quarter20.74%
Sales- P/S- EPS this Y33.80% Inst Trans0.04% Short Ratio9.87 Perf Half Y7.32%
Book/sh3.29 P/B2.50 EPS next Y-0.60% ROA-47.70% Target Price- Perf Year-40.38%
Cash/sh3.28 P/C2.50 EPS next 5Y- ROE-53.40% 52W Range5.76 - 14.25 Perf YTD4.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.39% Beta-
Dividend %- Quick Ratio16.70 Sales past 5Y- Gross Margin- 52W Low42.53% ATR0.46
Employees70 Current Ratio16.70 Sales Q/Q- Oper. Margin- RSI (14)54.00 Volatility4.68% 5.43%
OptionableYes Debt/Eq0.00 EPS Q/Q32.20% Profit Margin- Rel Volume0.80 Prev Close8.29
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume189.94K Price8.21
Recom1.80 SMA200.45% SMA509.87% SMA2004.90% Volume151,568 Change-0.97%
Jan-07-21Initiated Mizuho Buy $16
Jun-08-20Upgrade Goldman Neutral → Buy $15
Mar-25-19Downgrade Goldman Buy → Neutral $17 → $16
Mar-15-19Initiated Raymond James Outperform
Jul-16-18Initiated Wedbush Outperform $22
Jul-16-18Initiated JP Morgan Overweight $18
Jul-16-18Initiated Goldman Buy $18
Jan-11-21 08:00AM  
Jan-05-21 08:00AM  
Dec-17-20 01:43PM  
Dec-07-20 08:00AM  
Dec-04-20 11:13AM  
Dec-03-20 08:52AM  
Nov-09-20 08:00AM  
Nov-05-20 08:00AM  
Nov-04-20 11:02AM  
Nov-02-20 12:33PM  
Oct-07-20 12:46PM  
Sep-29-20 10:48AM  
Sep-11-20 08:00AM  
Sep-02-20 12:00PM  
Aug-31-20 08:00AM  
Aug-13-20 03:30PM  
Aug-06-20 08:00AM  
Aug-04-20 08:28AM  
Aug-03-20 04:05PM  
Jul-15-20 07:58PM  
Jul-08-20 03:44PM  
Jul-06-20 05:10PM  
Jul-05-20 07:00AM  
Jun-30-20 08:00AM  
Jun-24-20 08:20PM  
Jun-22-20 06:54PM  
Jun-20-20 07:10PM  
Jun-17-20 12:40PM  
Jun-16-20 03:03PM  
Jun-15-20 11:00AM  
Jun-13-20 09:09AM  
Jun-12-20 10:45AM  
Jun-11-20 03:09PM  
Jun-08-20 04:30PM  
Jun-05-20 08:30AM  
May-14-20 08:00AM  
May-07-20 07:30AM  
May-06-20 07:00AM  
Apr-30-20 08:00AM  
Apr-28-20 04:30PM  
Apr-17-20 08:11AM  
Apr-16-20 08:00AM  
Apr-07-20 01:21PM  
Mar-03-20 08:00AM  
Feb-26-20 08:30AM  
Feb-24-20 08:30AM  
Feb-20-20 08:30AM  
Feb-16-20 08:25AM  
Feb-06-20 08:30AM  
Feb-05-20 08:30AM  
Jan-13-20 08:00AM  
Jan-06-20 08:30AM  
Dec-19-19 09:54PM  
Dec-11-19 09:47AM  
Dec-09-19 07:45AM  
Dec-07-19 05:30PM  
Dec-01-19 09:30AM  
Nov-26-19 04:05PM  
Nov-13-19 08:00AM  
Nov-11-19 08:30AM  
Nov-06-19 09:00AM  
Oct-30-19 09:31AM  
Oct-16-19 08:30AM  
Oct-09-19 08:14AM  
Oct-08-19 09:56AM  
Sep-04-19 08:30AM  
Aug-08-19 08:00AM  
Aug-06-19 08:30AM  
Jul-12-19 02:29PM  
Jun-24-19 04:05PM  
Jun-22-19 07:57AM  
Jun-06-19 04:05PM  
May-09-19 08:00AM  
May-06-19 04:05PM  
May-01-19 08:11PM  
Apr-29-19 04:32PM  
Apr-24-19 08:30AM  
Apr-07-19 06:00PM  
Mar-20-19 12:07PM  
Mar-19-19 07:30AM  
Mar-15-19 01:32PM  
Mar-06-19 04:05PM  
Feb-25-19 08:15AM  
Feb-21-19 08:00AM  
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Booth BruceDirectorJun 29Buy8.001,250,00010,000,0001,250,000Jul 01 04:48 PM